glp-1 agonists names glp 1 receptor brand Understanding Agonists: Key Insights for Payers GI Adverse Effects of Glucagon-Like

Description

WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk

REFERENCES CDC

doi: 10.1210/jc.2003-030049

Each microdosing plan is tailored to your body composition, health goals, and how your body responds to treatment, for optimal weight management results